Photo from hmpgloballearningnetwork.com
Jun 17, 2023, 15:37
Super results in transfusion-dependent patients on ruxolitinib – Francesco Passamonti
It was a great honor to present at EHA 2023 on behalf of all investigators results of the ACE-536-MF-001 trial on luspatercept in patients with myelofibrosis and anemia. Super results in transfusion-dependent patients on ruxolitinib: a 32% rate of transfusion-independency over time with 53% of the patients with >50% reduction of transfusion burden. This allowed to keep stable the dose of ruxolitinib and the spleen size. All with a safe profile!
Source: Francesco Passamonti/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 18, 2024, 18:36
Dec 18, 2024, 18:34
Dec 18, 2024, 18:31
Dec 18, 2024, 18:28
Dec 18, 2024, 18:24
Dec 18, 2024, 18:18
Dec 18, 2024, 18:09
Dec 18, 2024, 18:05
Dec 18, 2024, 18:02